NSE · SHEEL · Miscellaneous
Sheel Biotech Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹102 Cr with net profit ₹11 Cr — a 10.4% net margin, versus 11.32% the period before.
Shareholding
As of 2026-03-31
- Promoter72.3%
- Public18.21%
- DII9.49%
395 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.53× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Miscellaneous · ranked #1 of 530 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Adani Ports & Special Economic Zone Ltd. | ₹3,83,402 Cr | 115.16 | 3.99 | 13.32% | 33.06% |
| Eternal Limited | ₹2,99,788 Cr | 1635 | 9.22 | 1.18% | 0.67% |
| BSE Limited | ₹1,43,789 Cr | 182.44 | 21.58 | 37.42% | 51.66% |
| GAIL (India) Ltd. | ₹1,14,170 Cr | 76.83 | 1.28 | 8.51% | 5.34% |
| GMR Airports Limited | ₹1,09,718 Cr | 358.31 | — | -10.6% | 1.19% |
| Mazagon Dock Shipbuilders Ltd. | ₹93,548 Cr | 36.21 | 9.59 | 26.48% | 21.23% |
| One 97 Communications Ltd. | ₹85,371 Cr | 105.25 | 5.33 | 4.55% | 7.25% |
| Meesho Limited | ₹84,197 Cr | — | 19.17 | -28.13% | -8.68% |
| Swiggy Limited | ₹81,680 Cr | — | 4.46 | -22.68% | -18.02% |
| Info Edge (India) Ltd. | ₹80,667 Cr | 142.5 | 2.13 | 3.82% | 0.44% |
| Sheel Biotech Limited(this company) | — | 11.76 | 1.09 | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashSheel Biotech Limited is listed in the Miscellaneous sector. The company has an EPS of 5.78 and a Book Value of 62.4. Its ROCE stands at 14.72%, and the debt-to-equity ratio is 0.26.
Positives
- +The company's revenue increased from Rs 63.2515527 Cr in Mar 2021 to Rs 102.2708 Cr in Mar 2025.
- +Net profit increased from Rs 4.797667 Cr in Mar 2021 to Rs 10.6361 Cr in Mar 2025.
- +The debt-to-equity ratio is 0.26, indicating low leverage.
- +Promoter holding of 72.2968% as of Mar 2026 is substantial.
- +There are no promoter pledged shares.
Negatives
- −The company is under the ESM (Enhanced Surveillance Measure) framework, specifically ESM Stage 1.
- −FII holding decreased to 0% in Mar 2026 from 2.2798% in Oct 2025.
- −DII holding decreased to 9.4927% in Mar 2026 from 10.2493% in Oct 2025.
- −The number of shareholders decreased from 636 in Oct 2025 to 395 in Mar 2026.
Financial Performance
Sheel Biotech Limited's net profit increased to Rs 10.6361 Cr in Mar 2025 from Rs 10.4747 Cr in Mar 2024. Revenue also increased to Rs 102.2708 Cr in Mar 2025 from Rs 92.5464 Cr in Mar 2024. Over the last five years, revenue has grown from Rs 63.2515527 Cr in Mar 2021 to Rs 102.2708 Cr in Mar 2025.
Profitability & Returns
The company reported an EPS of 5.78. Its Return on Capital Employed (ROCE) is 14.72%. For the fiscal year ending Mar 2025, the company's EBITDA was Rs 14.5896 Cr, up from Rs 13.7312 Cr in Mar 2024. Net profit for Mar 2025 was Rs 10.6361 Cr.
Balance Sheet
Sheel Biotech Limited has a debt to equity ratio of 0.26, indicating a relatively low reliance on borrowed funds. The company's book value per share is 62.4.
Ownership & Pledges
As of Mar 2026, promoters held 72.2968% of the company's shares. Public shareholding was 18.2105%, and DIIs held 9.4927%. There were no pledged shares by promoters. The total number of shareholders was 395.
Regulatory & Surveillance
The company is currently under the ESM (Enhanced Surveillance Measure) framework, specifically ESM Stage 1. This indicates increased monitoring by regulatory bodies.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.